UK's NICE rejects use of Zurampic (febuxostat + lesinurad) in gout- Gruenenthal
The National Institute for Health and Care Excellence has published draft guidelines preventing adults with gout from access to Zurampic (febuxostat + lesinurad) therapy, from Gruenenthal, for treating gout. NICE has published an appraisal consultation document rejecting the drug’s use for treating gout in patients whose serum uric acid is above the target level despite an adequate dose of a xanthine oxidase inhibitor alone. Evidence from two randomised controlled trials showed that a target serum uric acid level is reached in more people having Zurampic (lesinurad) plus the XOI allopurinol than in those taking the latter the drug alone.
Comment: The European Commission granted marketing authorisation for Zurampic (lesinurad) 200mg in combination with a xanthine oxidase inhibitor in 2016, for the adjunctive treatment of hyperuricemia in adult gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of an XOI alone.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins